-0.77%
18.21%
14.29%
21.13%
22.57%
43.33%
23.15%
AI Spotlight on ORNAV
Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally.It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services.
In addition, it markets and sells veterinary drugs manufactured by other international companies.The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets.Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics.
Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
Market Data
| Last Price | 51.6 |
| Change Percentage | -0.77% |
| Open | 52.2 |
| Previous Close | 52 |
| Market Cap ( Millions) | 7333 |
| Volume | 59005 |
| Year High | 52.9 |
| Year Low | 32.5 |
| M A 50 | 45.17 |
| M A 200 | 43.19 |
Financial Ratios
| FCF Yield | 2.33% |
| Dividend Yield | 3.10% |
| ROE | 40.41% |
| Debt / Equity | 27.78% |
| Net Debt / EBIDTA | 14.65% |
| Price To Book | 7.99 |
| Price Earnings Ratio | 22.25 |
| Price To FCF | 42.96 |
| Price To sales | 5.15 |
| EV / EBITDA | 16.32 |
News
- Jan -31 - 3 Reliable Dividend Stocks Offering Yields Up To 4.5%
- Jan -30 - Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
- Jan -28 - Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025
- Jan -15 - Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024
- Jan -15 - Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
- Jan -13 - 79,345 Orion Corporation A shares converted into B shares
- Jan -07 - Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
- Jan -02 - 3 Leading Dividend Stocks Yielding Up To 8.5%
- Dec -30 - Orion and Marinus terminate agreement for ganaxolone in Europe
- Dec -19 - CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
- Dec -19 - Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
- Dec -18 - Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
- Dec -12 - Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
- Nov -27 - 142,701 Orion Corporation A shares converted into B shares
- Nov -26 - 3 Prominent Dividend Stocks For November 2024
- Nov -22 - Orion Research Foundation grants EUR 1,109,000 for research in 2025
- Nov -19 - Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
- Nov -01 - Orion Corporation: Managers’ transactions – Henrik Stenqvist
- Oct -29 - Orion Group Interim Report January–September 2024
- Oct -24 - Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Generics and Consumer Health
Expected Growth : 8.5 %
What the company do ?
Generics and Consumer Health from Orion Oyj refers to the segment of the Finnish pharmaceutical company that focuses on developing and marketing affordable generic medications and consumer healthcare products.
Why we expect these perspectives ?
Orion Oyj's Generics and Consumer Health segment growth of 8.5% is driven by increasing demand for affordable medicines, strategic product launches, and expansion into emerging markets. Additionally, the company's focus on R&D and partnerships has enabled it to capitalize on opportunities in the growing self-care market, further boosting segment growth.
Segment n°2 -> Branded Products
Expected Growth : 8.0 %
What the company do ?
Orion Oyj's branded products include pharmaceuticals, diagnostics, and veterinary products, offering a range of proprietary medicines and healthcare solutions.
Why we expect these perspectives ?
Orion Oyj's branded products growth is driven by increasing demand for specialty pharmaceuticals, particularly in the oncology and respiratory therapy segments. Strong product pipeline, strategic partnerships, and expansion into emerging markets also contribute to the 8.0% growth. Additionally, investments in digitalization and operational efficiency enable the company to maintain a competitive edge.
Segment n°3 -> Innovative Medicines
Expected Growth : 9.5 %
What the company do ?
Innovative Medicines from Orion Oyj is a Finnish pharmaceutical company that develops and manufactures innovative, value-added medicines for humans and animals.
Why we expect these perspectives ?
Orion Oyj's Innovative Medicines segment growth is driven by strong demand for its Easyhaler product portfolio, particularly in Europe and Japan. The company's strategic investments in R&D, successful product launches, and expanding presence in emerging markets also contribute to its 9.5% growth. Additionally, Orion's focus on specialty care and rare diseases, as well as its partnerships and collaborations, further support its growth momentum.
Segment n°4 -> Animal Health
Expected Growth : 7.5 %
What the company do ?
Animal Health from Orion Oyj provides veterinary pharmaceuticals and services to improve animal welfare and productivity.
Why we expect these perspectives ?
Orion Oyj's Animal Health segment growth of 7.5% is driven by increasing pet ownership, rising demand for veterinary care, and growing awareness of animal health. Additionally, the company's strong product portfolio, including veterinary pharmaceuticals and diagnostics, contributes to its growth. Expanding distribution channels and strategic partnerships also support the segment's growth.
Segment n°5 -> Fermion
Expected Growth : 8.8 %
What the company do ?
Fermion Oyj, a Finnish pharmaceutical company, develops and manufactures high-quality active pharmaceutical ingredients (APIs) for the global market.
Why we expect these perspectives ?
Fermion from Orion Oyj's 8.8% growth is driven by increasing demand for pharmaceuticals, strategic partnerships, and expansion into emerging markets. Additionally, investments in R&D, process optimization, and cost savings initiatives contribute to the company's growth momentum.
Segment n°6 -> Translation Differences and Other Operations
Expected Growth : 6.0 %
What the company do ?
Translation Differences refer to variations in language translations, while Other Operations from Orion Oyj involve managing and reconciling these differences to ensure consistency across languages and regions.
Why we expect these perspectives ?
Orion Oyj's 6.0% growth in Translation Differences and Other Operations is driven by favorable currency fluctuations, strategic acquisitions, and improved operational efficiency. Additionally, the company's diversified product portfolio and expansion into emerging markets have contributed to the growth. Furthermore, effective cost management and investments in digital transformation have also supported the segment's growth.
Orion Oyj Products
| Product Range | What is it ? |
|---|---|
| Orion Pharma | Develops and manufactures pharmaceuticals, including prescription and self-care products |
| Orion Diagnostica | Develops and manufactures diagnostic tests and instruments for healthcare professionals |
| Orion Animal Health | Develops and manufactures veterinary pharmaceuticals and feed additives for animal health |
| Contract Manufacturing | Provides contract manufacturing services for pharmaceutical and biotechnology companies |
| Active Pharmaceutical Ingredients (APIs) | Develops and manufactures active pharmaceutical ingredients for pharmaceutical companies |
Orion Oyj's Porter Forces
Threat Of Substitutes
The threat of substitutes for Orion Oyj is medium, as there are some alternatives available in the market, but they are not very attractive to customers.
Bargaining Power Of Customers
The bargaining power of customers for Orion Oyj is low, as customers have limited options and the company has a strong brand presence.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Orion Oyj is medium, as the company relies on a few key suppliers, but has some flexibility in its supply chain.
Threat Of New Entrants
The threat of new entrants for Orion Oyj is high, as the industry has low barriers to entry and new companies can easily enter the market.
Intensity Of Rivalry
The intensity of rivalry for Orion Oyj is high, as the company operates in a highly competitive industry with many established players.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 18.35% |
| Debt Cost | 3.95% |
| Equity Weight | 81.65% |
| Equity Cost | 5.64% |
| WACC | 5.33% |
| Leverage | 22.47% |
Orion Oyj : Quality Control
Orion Oyj passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| QIA.DE | QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for … |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, … |
| ROVI.MC | Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are … |
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| VIRP.PA | Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Sanofi
A-Score
1-Year Total Return ->
🥈
Recordati
A-Score
1-Year Total Return ->
🥉
Orion
A-Score
1-Year Total Return ->
4
Qiagen
A-Score
1-Year Total Return ->
5
Rovi
A-Score
1-Year Total Return ->
6
